Clinical Immunology - Autoimmune Thyroid Serology

Anti-TSH receptor antibodies

Anti-TRAB antibodies (also known as TRAb, from Thyrotropin Receptor Antibodies) are autoantibodies directed against the thyroid-stimulating hormone (TSH) membrane receptor expressed on the surface of thyroid cells. They are the central serological marker of Graves' disease, the most common cause of persistent hyperthyroidism in the general population. Depending on their mechanism of action on the receptor, anti-TRABs are subdivided into stimulating antibodies (TSAb), which mimic the action of TSH and lead to chronic thyroid hyperstimulation, blocking antibodies (TBAb), which inhibit TSH binding and can cause hypothyroidism, and neutral antibodies, with no clear functional effect. In clinical practice, stimulating forms predominate, and are responsible for the classic Graves' disease triad: hyperthyroidism, diffuse goiter and orbitopathy. Detection and quantification of anti-TRAB play a diagnostic, prognostic and decision-making role, notably in guiding the duration of antithyroid treatment, anticipating the risk of relapse and monitoring during pregnancy.

Mechanism of action and functional classification

The TSH receptor (TSHR) is a G protein-coupled receptor expressed mainly on thyrocytes, but also on orbital and pretibial fibroblasts, which explains the orbitopathy and pretibial myxedema observed in Graves' disease. Anti-TRAbs bind to the extracellular domain of this receptor and exert variable effects depending on their functional class.

Class	Action on the TSHR	Clinical consequence	Frequency
Thyroid-stimulating immunoglobulins (TSIs)	Activation of the receptor, mimicking TSH	Hyperthyroidism, goiter, orbitopathy	Predominant in active Basedow's disease
Blocking antibodies (TBAb)	Competitive TSH binding blockade	Autoimmune hypothyroidism, thyroid atrophy	Less frequent; possible in advanced Hashimoto's thyroiditis
Neutralizing antibodies	Liaison without net functional effect	No direct clinical consequences	Variables; detected according to the method used

ℹ️ First-generation tests (competitive binding assays, or TBII) measure the overall ability of antibodies to displace labeled TSH from its receptor, without distinguishing between stimulating and blocking forms. Second and third-generation assays, particularly cell-based bioassays (TSAb), allow antibodies to be differentiated according to their functional activity and offer improved sensitivity in subclinical or early forms.

Graves' disease: clinical presentation

Graves' disease is an autoimmune thyroiditis characterized by chronic stimulation of the TSH receptor by stimulating antibodies, leading to excessive and uncontrolled production of thyroid hormones. It represents the most common cause of endogenous hyperthyroidism, with an estimated prevalence of 0.5 to 1 % of the population, primarily affecting women between 20 and 50 years of age.

Palpitations, sinus tachycardia or atrial fibrillation, sometimes inaugural
Weight loss despite a preserved or increased appetite
Nervousness, irritability, anxiety, insomnia, and fine tremor of the extremities
Heat intolerance and excessive sweating
Diffuse, homogeneous, and vascular goiter (bruit audible on auscultation)
Graves' ophthalmopathy: exophthalmos, eyelid retraction, diplopia, eye pain
Proximal myopathy, fatigability, and exertional dyspnea
Pretibial myxedema (dermopathy) in severe forms, a nearly pathognomonic sign
Oligo-amenorrhea or infertility in women; erectile dysfunction in men

Associated biological values and interpretation

Parameter	Expected outcome in active Basedow's disease	Interpretation
Ultrasensitive TSH	Collapsed or undetectable	Suppression of elevated thyroid hormones by negative feedback
Free T4 (fT4)	High	Reflection of hyperthyroidism; first parameter to normalize under treatment
Free T3 (fT3)	Elevated (often proportionally more than T4)	Predominance of T3 frequent in Graves' disease; prognostic value of severity
Anti-TRAB	Positive, high title	Diagnostic confirmation of Graves' disease; correlates with activity and risk of relapse
Anti-TPO (anti-thyroperoxidase)	Positive in 70 to 80 % of cases	Thyroid autoimmunity markers; not specific to Graves' disease
Anti-thyroglobulin (anti-Tg)	Positive in about 50 % of cases	Less specific; useful in the overall autoimmune thyroid assessment
CBC (complete blood count)	Sometimes mild leukopenia	To monitor under synthetic antithyroid drugs (risk of agranulocytosis)

Diagnostic role of TRAB antibodies

Anti-TRAB antibodies show a sensitivity of 95–99%% and a specificity exceeding 99%% for Graves' disease when measured by second or third-generation methods. Their measurement is indicated in several specific clinical situations, where they help refine the differential diagnosis or guide management.

Confirmation of Graves' disease diagnosis in the presence of hyperthyroidism with suppressed TSH
Distinction between Graves' disease and subacute thyroiditis or postpartum thyroiditis (anti-TRAb negative in the latter two)
Hyperthyroidism in Pregnant Women, to Assess the Risk of Neonatal Graves' Disease
Pre-conception assessment in a patient with a history of treated Graves' disease
Isolated orbitopathy without evident biological hyperthyroidism (euthyroid Graves' disease)
Assessment of remission before stopping antithyroid drug treatment
Suspicion of hypothyroidism due to blocking antibodies in advanced Hashimoto's thyroiditis

Prognostic value and therapeutic monitoring

The title of anti-TRAb is one of the best predictors of the evolution of Graves' disease under medical treatment. Its kinetics under antithyroid drugs provide important decision-making information, particularly for the optimal duration of treatment and the timing of considering definitive therapy.

Clinical situation	Interpretation of anti-TRAB title	Action to take
Very high reading at diagnosis	Intense autoimmune activity; probable severe disease	Initiate antithyroid treatment; rapidly assess definitive option
Title normalization after 12 to 18 months of treatment	Likely immunologic remission	Treatment discontinuation is possible; reduced risk of relapse (30 to 40 %)
Persistence of a high title after 18 months	Absence of immunological remission	Recommended definitive treatment: radioactive iodine or total thyroidectomy
Re-escalation of the title in progress	Relapse or autoimmune flare	Therapeutic adjustment; re-evaluation of long-term strategy
Positive anti-TRAB after total thyroidectomy	Risk of persistent or recurrent orbitopathy	Ophthalmic follow-up; antibodies can persist for years after surgery

ℹ️ Immunological remission, defined by the negativity of anti-TSHR antibodies, does not guarantee the absence of clinical relapse. Approximately 30-50 % of patients achieve durable remission after 18 to 24 months of antithyroid treatment. Factors associated with a high risk of relapse include a high anti-TSHR antibody titer at the cessation of treatment, a large goiter, very high T3 at diagnosis, and active smoking.

Anti-TRAB and pregnancy

Pregnancy is a particularly important clinical situation for monitoring TRAb. These antibodies freely cross the placental barrier from the second trimester and can stimulate or block the TSH receptor of the fetus and newborn, with potentially severe consequences for neonatal thyroid development.

Context	Fetal or neonatal risk	Recommended surveillance
Active Graves' disease during pregnancy	Fetal hyperthyroidism, growth retardation, prematurity, transient neonatal hyperthyroidism	Anti-TRAB dosage at 24-28 weeks and 36 weeks; specialized fetal monitoring
History of Graves' disease, definitively treated (iodine or surgery)	Neonatal hyperthyroidism if high persistent TRAbs	Anti-TRAB dosage in the first trimester; if high, repeat at 18-22 and 30-34 weeks
Very high maternal anti-TRAB (greater than 3 times the upper limit)	Significant risk of neonatal Graves' disease	Fetal echocardiogram, fetal thyroid ultrasound, neonatal resuscitation
Predominant blocking antibodies	Transient neonatal hypothyroidism	Early neonatal thyroid assessment; clinical monitoring of the newborn

ℹ️ In pregnant women with Graves' disease or a history of treated Graves' disease, international guidelines (ATA 2017, ETA 2018) recommend measuring TRAb antibodies in the first trimester. A level above three times the upper limit of normal warrants enhanced fetal monitoring and coordination with the neonatology team. Neonatal hyperthyroidism, although transient, can lead to serious cardiac and neurological complications if not promptly detected.

Available assay methods

Generation	Method	What it measures	Advantages and disadvantages
First Generation (TB-II)	Competitive binding assay with labeled TSH	Overall ability to displace TSH from the receptor	Accessible, quantitative; does not distinguish between stimulants and blockers
Second generation	TBII with recombinant human receptor (RR-TBII)	Recombinant human TSHR Binding	Improved sensitivity over the first generation; common reference method in Quebec
Third generation (TSAb)	Cell-based bioassay (cAMP or reporter gene)	Targeted Specific Functional Activities (TSAb)	Distinguish TSAb and TBAb; better prognostic value; less available in routine

Consult at Clinique Omicron

Clinique Omicron offers a comprehensive medical evaluation at its service points in Quebec for patients presenting with symptoms of hyperthyroidism, thyroid function abnormalities, or suspected autoimmune thyroid disease. Our physicians are capable of prescribing and interpreting TRAB antibody levels in their clinical context, initiating appropriate management, and referring to an endocrinologist or an ophthalmologist specializing in orbitopathy when necessary. Special attention is given to pregnant patients or those planning a pregnancy with a history of autoimmune thyroid disease. Book an appointment at one of our service points on the South Shore or at one of our branches in Quebec. Teleconsultation is also available for an initial evaluation or a review of biological results.

The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.

Omicron Clinic

Need to consult a doctor?

Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.

No appointment necessary Private clinic Family doctor

Insurance receipts. 7j/7. No family doctor required.

At the clinic

At home

On line

Health assessments

Our programs